Birinapant (TL32711): SMAC Mimetic IAP Antagonist for Apoptosis Research

Executive Summary: Birinapant (TL32711) is a bivalent SMAC mimetic and a potent inhibitor of inhibitor of apoptosis proteins (IAPs), including XIAP and cIAP1, with Kd values of 45 nM and <1 nM respectively (source: product_spec). The compound binds to the BIR3 domains of IAPs, leading to rapid degradation of cIAP1/2 and inhibition of TNF-mediated NF-κB activation (source: DOI). Birinapant enhances TRAIL-induced apoptosis and increases caspase-8:RIPK1 complex formation, resulting in caspase activation. In vivo, it demonstrates robust tumor growth inhibition and caspase-3 activation in xenograft models (source: internal_article). The compound is supplied by APExBIO for research in apoptosis, cancer biology, and IAP-mediated signaling pathways.

Biological Rationale

Apoptosis, or programmed cell death, is a critical pathway for maintaining tissue homeostasis and eliminating malignant cells. Inhibitor of apoptosis proteins (IAPs) such as XIAP, cIAP1, and cIAP2 impede apoptosis by inhibiting caspases, thereby contributing to cancer cell survival and resistance to therapy (source: DOI). SMAC mimetics, including Birinapant, mimic the endogenous SMAC protein to antagonize IAP function, restore apoptotic sensitivity, and enhance the efficacy of chemotherapeutic regimens (source: internal_article).

Mechanism of Action of Birinapant (TL32711)

Birinapant (TL32711) is a bivalent SMAC mimetic that binds with high affinity to the BIR3 domains of cIAP1, cIAP2, and XIAP, as well as the BIR domain of ML-IAP (source: product_spec). Upon binding, Birinapant induces rapid ubiquitination and proteasomal degradation of TRAF2-bound cIAP1/2. This event blocks TNF-mediated activation of the NF-κB pathway and triggers the assembly of the caspase-8:RIPK1 complex, leading to caspase-8 activation and apoptosis (source: internal_article). The pan-IAP antagonism of Birinapant also sensitizes tumor cells to TRAIL, a ligand that induces extrinsic apoptosis, further enhancing apoptosis induction in cancer cells (source: internal_article).

Evidence & Benchmarks

• Birinapant binds cIAP1 with a Kd of <1 nM and XIAP with a Kd of 45 nM, supporting its high affinity and specificity (source: product_spec).
• Rapid degradation of cIAP1 and cIAP2 upon Birinapant treatment is observed in cell-based assays, resulting in NF-κB inhibition (source: DOI).
• Birinapant enhances TRAIL potency and induces apoptosis in cancer cell lines, including inflammatory breast cancer and melanoma models (source: internal_article).
• In vivo, Birinapant significantly inhibits tumor growth and increases caspase-3 activation, as demonstrated in molecular imaging and xenotransplantation studies (source: internal_article).
• The compound is soluble at ≥40.35 mg/mL in DMSO and ≥46.9 mg/mL in ethanol, but insoluble in water (source: product_spec).

This article expands upon the mechanistic insights outlined in 'Precision SMAC Mimetic for Apoptosis', clarifying the efficacy parameters and solubility characteristics of Birinapant (TL32711) for bench applications. Additionally, it updates translational workflow recommendations compared to 'Strategic Deployment of SMAC Mimetics' by incorporating new in vivo benchmarks.

Applications, Limits & Misconceptions

Birinapant (TL32711), available as the A4219 kit from APExBIO, is primarily used in apoptosis research, cancer biology, and studies involving IAP-mediated signaling pathways. Its ability to enhance TRAIL-induced apoptosis and inhibit TNF-mediated NF-κB activation makes it valuable for dissecting resistance mechanisms in cancer cells (source: internal_article). The compound is administered via intraperitoneal injection in animal models, typically at 30 mg/kg (source: product_spec).

Common Pitfalls or Misconceptions

• Birinapant is not effective in models lacking functional TNF or TRAIL signaling, as its pro-apoptotic effects require these upstream triggers (source: DOI).
• It should not be used as a direct substitute for general caspase activators; its mechanism is specific to IAP antagonism (workflow_recommendation).
• Solubility in aqueous buffers is poor; stock solutions should be prepared in DMSO or ethanol and stored at -20°C (source: product_spec).
• Therapeutic translation is limited by the compound's pharmacokinetic properties and delivery challenges in humans (workflow_recommendation).
• Birinapant does not restore apoptosis in cancers with irreversible caspase gene defects (source: internal_article).

Workflow Integration & Parameters

Protocol Parameters

• apoptosis induction assay | 10 mM in DMSO | in vitro cell culture | Ensures accurate dosing and compound stability | workflow_recommendation
• tumor xenograft model | 30 mg/kg via i.p. injection | in vivo efficacy | Proven to inhibit tumor growth and activate caspase-3 | product_spec
• stock solution storage | -20 °C, short-term | all applications | Maintains compound integrity | product_spec
• solubility testing | ≥40.35 mg/mL in DMSO | solution prep | Required for high-concentration stock solutions | product_spec
• apoptosis rescue in MDM1-low CRC | combine with chemoradiation | CRC models | Restores sensitivity in resistant colorectal cancer cells | DOI

Conclusion & Outlook

Birinapant (TL32711) stands out as a robust tool for investigating IAP-mediated apoptosis and overcoming chemoresistance in cancer research. Its validated efficacy in both in vitro and in vivo models supports its utility for dissecting cell death pathways and enhancing sensitivity to chemoradiation, particularly in contexts involving MDM1 or p53 modulation (source: DOI). Ongoing refinement of workflow integration and compatibility with biomarker-driven strategies is essential for maximizing research impact. For further information and product specifications, refer to the Birinapant (TL32711) product page from APExBIO.